Trials / Terminated
TerminatedNCT05222269
[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients
A Prospective, International, Multi-centre, Open-label, Single-arm Phase II Study Investigating the Predictive Value of [68Ga]Ga PentixaFor PET Imaging in Primary and Isolated Secondary CNS Lymphoma Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Pentixapharm AG · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This will be an open, single-arm, international, multicentre, phase II imaging study to assess the predictive value of \[68Ga\]Ga PentixaFor PET imaging in primary and isolated secondary central nervous system lymphoma (CNSL) patients scheduled to undergo induction chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-PTF | 68Ga-PTF will be injected intravenously at three time points during the course of the standard treatment of the patient. |
Timeline
- Start date
- 2022-10-05
- Primary completion
- 2023-01-25
- Completion
- 2023-01-25
- First posted
- 2022-02-03
- Last updated
- 2025-09-05
Locations
2 sites across 2 countries: Denmark, France
Source: ClinicalTrials.gov record NCT05222269. Inclusion in this directory is not an endorsement.